ClinicalTrials.gg
CompletedNCT02598596TRIPLEUpdated Oct 11, 2021

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

A Phase 2 interventional study of Pegloticase and Azathioprine in Gout, sponsored by Ampel BioSolutions, LLC. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Ampel BioSolutions, LLC · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
7th of 14
132 · median 93
Started
2015
the only one that year
Phase 2
3 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
1 of 14
Ampel BioSolutions, LLC

Among the 14 studies testing pegloticase in Gout, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 6th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.

Read the detailed description

This is an exploratory open-label, multicenter study to evaluate the effectiveness of a 16-week high zone tolerance regimen of pegloticase on response to therapy (serum uric acid \<6 mg/dL) with this drug in adult hyperuricemic patients with gout refractory to conventional therapy.

Eligible subjects will receive 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.

Subjects will be monitored for efficacy and safety endpoints through Week 17. Subjects will also have blood drawn for pegloticase levels prior to each dose on Weeks 2, 3, 5, 7, 9, 11, 13,15, and 17. Following Study Week 17, subjects will have an option to continue dosing for an additional 8 weeks.

A subset of subjects will participate in additional pharmacokinetic (PK) assessments.

The study duration, per enrolled patient, will be approximately 26 weeks including a 2-week screening period, a 16-week treatment period (end of treatment [EOT] visit Week 17), and an optional 8-week dosing extension.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Refractory gout
  • Chronic gout
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (age ≥18 years) men and women of non-, with chronic gout to conventional therapy, defined as patients who have failed to normalize SUA and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose, or for whom these drugs are .
  2. Hyperuricemic - Screening visit SUA must be >6 mg/dL
  3. On gout flare prophylactic regimen for 7 days prior to the first dose.
  4. Willing and able to give and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed)

Exclusion criteria

Exclusion Criteria:

  1. Glucose-6-phosphate dehydrogenase (G6PD) deficiency (confirmed at Screening visit)
  2. Non-compensated congestive heart failure, uncontrolled arrhythmia, treatment for acute coronary syndrome (ACS) (myocardial infarction or unstable angina) or hospitalization for congestive heart failure within 3 months of screening or uncontrolled blood pressure (>160/100 mm Hg) at baseline (Screening and pre-dose at Week 1 visit )
  3. Women of defined as:

    • Pre- or perimenopausal (\<24 months of natural [spontaneous] amenorrhea).
    • \<6 weeks after surgical bilateral oophorectomy with or without hysterectomy.
  4. Prior treatment with pegloticase or another recombinant uricase
  5. Prior treatment or concomitant therapy with a polyethylene glycol (PEG) conjugated drug
  6. Known allergy to PEG products or history of anaphylactic reaction to a recombinant protein or porcine product
  7. Concurrent treatment with urate lowering agents (ULAs), such as allopurinol and febuxostat. Patients treated with these medications must discontinue treatment 7 days prior to the first dose of study drug
  8. Recipient of an drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
  9. Current liver disease as determined by (ALT) or aspartate transaminase (AST) levels >3 times (ULN)
  10. History of within 5 years other than basal cell skin cancer or carcinoma in situ of the cervix
  11. Has any other medical or psychological condition which, in the opinion of the Investigator, might create undue risk to the patient or interfere with the patient's ability to comply with the protocol requirements, or to complete the study
  12. Solid organ transplant recipients
  13. Uncontrolled hyperglycemia with a plasma glucose value >240 mg/dL at screening
  14. Currently on dialysis

    Additional Exclusion Criteria for Imaging Sub-study Only

  15. to receiving a gadolinium-based contrast agent (GBCA) or > 2 previous lifetime exposures to a GBCA
  16. Implanted pacemaker, certain older intracranial aneurysm clips, cochlear implants, certain prosthetic devices, implanted drug infusion pumps, neurostimulators, bone-growth stimulators, certain intrauterine devices, or any other type of iron-based metal implants.
  17. Any internal metallic objects such as bullets or shrapnel, as well as most surgical clips, pins, plates, screws, metal sutures, or wire mesh.

    Additional Exclusion Criteria for FDG-PET-CT Sub-study Only

  18. Contraindication to FDG

    Additional Exclusion Criteria for Pegloticase and AZA Therapy Arm Only

  19. Any active serious bacterial infection (2 weeks prior to screening) requiring antibiotic treatment
  20. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia, chronic bronchiectasis
  21. Current condition, including current or chronic treatment with systemic immunosuppressive agents (e.g., prednisone or equivalent dose >510 mg/day)
  22. At risk for tuberculosis. Specifically, subjects with: a) current clinical, radiographic, or laboratory evidence of active or latent tuberculosis; b) a history of active tuberculosis within the last 31 years even if it was treated; c) a history of active tuberculosis >31 years ago unless there is documentation that the prior anti-tuberculosis treatment was appropriate in duration and type
  23. Known history of surface antigen-positivity or hepatitis B DNA positivity
  24. Known history of RNA-positivity
  25. Known history of positivity
  26. Severe chronic renal impairment ( \<25 mL/min/1.73 m2)
  27. AZA treatment is contraindicated or considered inappropriate
  28. Subject has a homozygous or heterozygous thiopurine methyltransferase (TPMT) variant genotype
  29. Diagnosis of osteomyelitis
  30. Known hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome
  31. Concurrent use of a xanthine oxidase inhibitor
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Pegloticase regimen <120 kg - Main Study

    Subjects weighing \<120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.

    Biological: Pegloticase

  • Experimental
    Pegloticase regimen ≥120kg

    Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.

    Biological: Pegloticase

  • Experimental
    Pegloticase PK Sub-Study

    Subjects weighing \<120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.

    Biological: Pegloticase

  • Experimental
    Pegloticase Imaging Sub-Study

    A subset of subjects participating in the Main Study and weighing \<120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.

    Biological: Pegloticase

  • Experimental
    Pegloticase FDG-PET-CT Sub-Study

    A subset of subjects participating in the Main Study and weighing \<120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.

    Biological: Pegloticase

  • Experimental
    Pegloticase and Azathioprine

    Subjects weighing \<120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.

    Biological: Pegloticase · Drug: Azathioprine

Interventions

  • BiologicalPegloticase

    Pegloticase, IV

    Also known as: Krystexxa

  • Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily

    Also known as: Imuran

06

What researchers measure

Primary outcomes

  1. Normalization of serum uric acid (SUA) in subjects receiving a tolerizing regimen of pegloticase

    Determine response rate; the last 3 consecutive levels of SUA must be \<6 mg/dL

    Time frame: Week 17

  2. Normalization of serum uric acid (SUA) in subjects receiving pegloticase and azathioprine (AZA) immunosuppressive therapy

    Determine response rate; the last 3 consecutive levels of SUA must be \<6 mg/dL

    Time frame: Week 25

Secondary outcomes

  1. Change from baseline in SUA to end of Treatment

    Change from baseline

    Time frame: Baseline and Week 17

  2. Change from baseline in SUA to end of Treatment

    Change from baseline - AZA arm

    Time frame: Baseline and Week 25

  3. Proportion of subjects with SUA <5 mg/dL

    Proportion of subjects

    Time frame: Week 17

  4. Proportion of subjects with SUA <5 mg/dL

    Proportion of subjects - AZA arm

    Time frame: Week 25

  5. Proportion of subjects with SUA <2 mg/dL

    Proportion of subjects

    Time frame: Week 17

  6. Proportion of subjects with SUA <2 mg/dL

    Proportion of subjects - AZA arm

    Time frame: Week 25

  7. Infusion reactions (IRs) and anaphylaxis

    Incidence - AZA arm

    Time frame: Week 17

  8. Infusion reactions (IRs) and anaphylaxis

    Incidence

    Time frame: Week 25

  9. Incidence of anti-pegloticase antibodies

    Anti-pegloticase antibodies

    Time frame: Week 17

  10. Incidence of anti-pegloticase antibodies

    Anti-pegloticase antibodies - AZA arm

    Time frame: Week 25

  11. Mean titer of anti-pegloticase antibodies

    Anti-pegloticase antibodies

    Time frame: Week 17

  12. Mean titer of anti-pegloticase antibodies

    Anti-pegloticase antibodies AZA arm

    Time frame: Week 25

  13. Incidence of gout flares, adverse events (AEs), serious AEs (SAEs), and early terminations due to AEs

    Incidence

    Time frame: Week 17

  14. Incidence of gout flares, adverse events (AEs), serious AEs (SAEs), and early terminations due to AEs

    Incidence - AZA arm

    Time frame: Week 25

Other outcomes

  1. Relationship in change from baseline in SUA from baseline with rate of infusion reactions

    Correlation between change in SUA and infusion reactions

    Time frame: Baseline to Week 17

  2. Relationship in change from baseline in SUA from baseline with rate of infusion reactions

    Correlation between change in SUA and infusion reactions - AZA arm

    Time frame: Baseline to Week 25

  3. Compare trough pegloticase levels

    Descriptive statistics

    Time frame: Week 17

  4. Compare trough AZA levels

    Descriptive statistics

    Time frame: Week 25

  5. Ability of imaging to monitor treatment response

    To compare the ability of dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to monitor treatment response, in a subset of subjects weighing \< 120 kg

    Time frame: Baseline and Week 17

  6. Evaluate change from baseline carotid and aortic (chest) atherosclerosis

    Change from baseline as measured by fluorodeoxyglucose-positron emission tomography (FDG-PET-CT), in a subset of subjects weighing \< 120 kg

    Time frame: Baseline and Week 17

  7. Cmax of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

  8. Tmax of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

  9. AUC of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

  10. Terminal phase half-life of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

  11. CL of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

  12. Vss of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

  13. Accumulation Ratio (AR) of pegloticase in subjects weighing ≥ 120 kg and < 120 kg

    PK parameter

    Time frame: Up to Week 17

07

Study locations

11 sites
  • University of Alabama at Birminingham
    Birmingham, Alabama 35294, United States
  • Rheumatology Associates of North Alabama
    Huntsville, Alabama 35801, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01609, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Saint Paul Rheumatology
    Eagan, Minnesota 55121, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Buffalo Rheumatology and Medicine
    Orchard Park, New York 14127, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • ACME Research, LLC
    Orangeburg, South Carolina 29118, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Apr 2020, 52 months.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 52 months is above that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2015
First posted
Nov 6, 2015
StartActual
Dec 2015
Primary completionActual
Apr 13, 2020
CompletionActual
Apr 27, 2020
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02598596
Lead sponsor
Ampel BioSolutions, LLC
Collaborators
IND 2 Results LLC
Responsible party
Sponsor
First posted
Nov 6, 2015
Start date
Dec 2015
Primary completion
Apr 13, 2020
Completion
Apr 27, 2020
Last update
Oct 11, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegloticase

Start the discussion